Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTx-015 in Retinitis Pigmentosa (PERCEPT)
NCT07901751Phase 3Recruiting
- Sponsor
- Ray Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 3 trial of RTx-015 in retinitis pigmentosa (RP), sponsored by Ray Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
RTx-015
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT07901751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901751.